Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK.
Eduardo
E
Carracedo-Martínez
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000191:economics / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000191:economics* / Q000628:therapy; D016861:Cyclooxygenase Inhibitors / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D000077613:Etoricoxib; D006801:Humans; D010003:Osteoarthritis / Q000191:economics* / Q000628:therapy; D054328:Proton Pump Inhibitors; D011725:Pyridines / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use; D013450:Sulfones / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use; D006113:United Kingdom
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D054328:Proton Pump Inhibitors; D011725:Pyridines; D013450:Sulfones; D000077613:Etoricoxib